For the first time in its 13 year history, the Genome Sequencing and Analysis Conference (GSAC) devoted a morning s plenary session to proteomics, which included talks by Denis Hochstrasser, co-founder of GeneProt, Scott Patterson, vice president of proteomics at Celera, and Dolores Cahill, a protein array researcher at the Max-Planck Institute of Molecular Genetics in Berlin.
A patent and licensing dispute between Biosite and Xoma has disrupted a collaboration between Large Scale Biology Corporation (LSBC) and Biosite, and threatens to derail LSBC s efforts to develop protein microarrays, company officials told ProteoMonitor last week.
As structural biology companies race ahead to obtain x-ray crystallography structures of promising drug targets, the biggest hurdle has traditionally been getting access to tunable x-ray sources at synchrotrons.
Bruker Daltonics and Biacore have agreed to jointly develop an instrument system for analyzing proteins that combines surface plasmon resonance (SPR) and mass spectrometry, the companies said last week.
As a genomics-based biotech company, Millennium Pharmaceuticals has built some of its largest collaborations to date -- with companies such as Bayer and Aventis -- on the basis of its microarray and other gene expression technologies. But in recent months the Cambridge, Mass.-based company has indicated it is expanding its efforts in proteomics to augment its drug discovery arsenal.
In an effort to attract investors to its multi-dimensional liquid chromatography-based separation technology, Eichrom Technologies last week spun off its proteomics operations as a wholly-owned subsidiary called Eprogen.
Having outgrown the need for an in-house demonstration lab, Genomic Solutions announced earlier this month that it would spin off its costly proteomics research services business and form a new company, aptly named Proteomic Research Services (PRS).
Invitrogen plans to develop 2D gel electrophoresis technology for applications in proteomics using protein synthesis technology licensed from Gryphon Sciences, an Invitrogen spokesperson said last week.
The US Patent and Trademark Office has awarded Genomic Solutions US patent 6,302,159, entitled “Apparatus and method of carrying out flow through chemistry of multiple mixtures.” The patent covers technology developed by Genomic Solutions for its ProPrep and ProG
In the wake of the recent rash of deliveries of anthrax by mail in the US, DNA tests for pathogens used as biological weapons have come to be seen as the answer to the public s need for quick, reliable systems for detecting anthrax and other pathogens such as tularemia and smallpox.
Steering the scientific direction of proteomics is not an easy task, but participants at Defining the Proteomics Agenda, a conference held by the American Chemical Society Oct. 7-10 in Leesburg, Va., made tentative steps toward laying out what the field should try to accomplish.
Joanna Albala, a senior biomedical scientist at Lawrence Livermore National Lab, said her lab s new partnership with proteomics company Phylos is the outcome of a true networking opportunity at last year s Chips to Hits meeting in Philadelphia. It was there that executives from Phylos, a Lexington, Mass., developer of protein binders, happened to be on the lookout for a collaborator that could custom deliver target proteins. Albala sat down next to one of them during a luncheon in the exhibit hall.